Methylglyoxal modulates immune responses: relevance to diabetes
File(s)
Author(s)
Type
Journal Article
Abstract
Increased methylglyoxal (MG) concentrations and formation of advanced glycation end-products (AGEs) are major pathways of glycaemic damage in diabetes, leading to vascular and neuronal complications. Diabetes patients also suffer increased susceptibility to many common infections, the underlying causes of which remain elusive. We hypothesized that immune glycation damage may account for this increased susceptibility. We previously showed that the reaction mixture (RM) for MG glycation of peptide blocks up regulation of CD83 in myeloid cells and inhibits primary stimulation of T cells. Here, we continue to investigate immune glycation damage, assessing surface and intracellular cytokine protein expression by flow cytometry, T-cell proliferation using a carboxyfluorescein succinimidyl ester assay, and mRNA levels by RT-PCR. We show that the immunomodulatory component of this RM was MG itself, with MG alone causing equivalent block of CD83 and loss of primary stimulation. Block of CD83 expression could be reversed by MG scavenger N-acetyl cysteine. Further, MG within RM inhibited stimulated production of interleukin (IL)-10 protein from myeloid cells plus interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha from T cells. Loss of IL-10 and IFN-gamma was confirmed by RT-PCR analysis of mRNA, while TNF-alpha message was raised. Loss of TNF-alpha protein was also shown by ELISA of culture supernatants. In addition, MG reduced major histocompatibility complex (MHC) class I expression on the surface of myeloid cells and increased their propensity to apoptose. We conclude that MG is a potent suppressor of myeloid and T-cell immune function and may be a major player in diabetes-associated susceptibility to infection.
Date Issued
2010-06
Date Acceptance
2009-06-01
Citation
Journal of Cellular and Molecular Medicine, 2010, 14 (6b), pp.1806-1815
ISSN
1582-1838
Publisher
Wiley
Start Page
1806
End Page
1815
Journal / Book Title
Journal of Cellular and Molecular Medicine
Volume
14
Issue
6b
Copyright Statement
© 2009 The AuthorsJournal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.
Identifier
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19538479
Subjects
Science & Technology
Life Sciences & Biomedicine
Cell Biology
Medicine, Research & Experimental
Research & Experimental Medicine
methylglyoxal
advanced glycation
dendritic cells
T cells
diabetes
GLYCATION END-PRODUCTS
DENDRITIC CELLS
IN-VIVO
TYPE-1
EXPRESSION
MELLITUS
DISEASE
SYSTEM
SITES
LYMPHOCYTES
Antigens, CD
Apoptosis
Cell Proliferation
Cytokines
Diabetes Mellitus
Gene Expression Regulation
Histocompatibility Antigens Class I
Humans
Immunoglobulins
Immunomodulation
Membrane Glycoproteins
Myeloid Cells
Pyruvaldehyde
RNA, Messenger
T-Lymphocytes
T-Lymphocytes
Myeloid Cells
Humans
Diabetes Mellitus
Pyruvaldehyde
Immunoglobulins
Membrane Glycoproteins
RNA, Messenger
Antigens, CD
Histocompatibility Antigens Class I
Cytokines
Apoptosis
Cell Proliferation
Gene Expression Regulation
Immunomodulation
Biochemistry & Molecular Biology
0304 Medicinal and Biomolecular Chemistry
0601 Biochemistry and Cell Biology
1103 Clinical Sciences
Notes
Price, Claire L Hassi, Hafid O S Al English, Nicholas R Blakemore, Alexandra I F Stagg, Andrew J Knight, Stella C England Journal of cellular and molecular medicine J Cell Mol Med. 2010 Jun;14(6B):1806-15. Epub 2009 Jun 16. Increased methylglyoxal (MG) concentrations and formation of advanced glycation end-products (AGEs) are major pathways of glycaemic damage in diabetes, leading to vascular and neuronal complications. Diabetes patients also suffer increased susceptibility to many common infections, the underlying causes of which remain elusive. We hypothesized that immune glycation damage may account for this increased susceptibility. We previously showed that the reaction mixture (RM) for MG glycation of peptide blocks up regulation of CD83 in myeloid cells and inhibits primary stimulation of T cells. Here, we continue to investigate immune glycation damage, assessing surface and intracellular cytokine protein expression by flow cytometry, T-cell proliferation using a carboxyfluorescein succinimidyl ester assay, and mRNA levels by RT-PCR. We show that the immunomodulatory component of this RM was MG itself, with MG alone causing equivalent block of CD83 and loss of primary stimulation. Block of CD83 expression could be reversed by MG scavenger N-acetyl cysteine. Further, MG within RM inhibited stimulated production of interleukin (IL)-10 protein from myeloid cells plus interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha from T cells. Loss of IL-10 and IFN-gamma was confirmed by RT-PCR analysis of mRNA, while TNF-alpha message was raised. Loss of TNF-alpha protein was also shown by ELISA of culture supernatants. In addition, MG reduced major histocompatibility complex (MHC) class I expression on the surface of myeloid cells and increased their propensity to apoptose. We conclude that MG is a potent suppressor of myeloid and T-cell immune function and may be a major player in diabetes-associated susceptibility to infection.
Publication Status
Published
Date Publish Online
2009-06-16